title: Reduction of bladder activity on FDG PET/CT scan in patients with urinary bladder carcinoma. A prospective study with a patient-friendly protocol.
abstract: Oral hydration with large volume of fluid, high dose of diuretics and maximum bladder distension are frequently required to achieve an adequate urinary FDG clearance in an FDG PET/CT protocol for bladder cancer or pelvic tumour evaluation. Although most patients tolerated these procedures for eliminating urinary FDG activity, these procedures may be still unpleasant.
  
  
  OBJECTIVE
  Is there a more patient-friendly protocol which is less burdensome and yet provides a satisfactory FDG clearance in urine? In this study, we established a patient-friendly FDG PET/CT protocol without compromising urinary FDG clearance.
  
  
  METHODS
  23 patients with biopsy-proven urinary bladder cancers were recruited to evaluate the effectiveness of this patient-friendly protocol on reducing urinary bladder FDG activity. The patient-friendly protocol includes encouraging patients to take a tolerable amount of fluid, delaying the administration of low dose diuretic, shortening the urine holding time and using delayed imaging.
  
  
  RESULTS
  All of the patients tolerated this patient-friendly procedure well. In addition, the patient-friendly protocol was effective in reducing FDG activity in the urine. One hundred percent of primary bladder cancer were visualized on the FDG PET/CT images using this patient-friendly protocol.
  
  
  CONCLUSIONS
  This patient-friendly FDG PET/CT protocol is less intrusive yet effective in reducing urinary FDG activity.
authors.forename: S-C
authors.initials: SC
authors.lastname: Tsai
authors.forename: Y-C
authors.initials: YC
authors.lastname: Ou
authors.forename: C-L
authors.initials: CL
authors.lastname: Cheng
authors.forename: J-R
authors.initials: JR
authors.lastname: Li
authors.forename: Y-C
authors.initials: YC
authors.lastname: Lin
authors.forename: H-C
authors.initials: HC
authors.lastname: Ho
authors.forename: K-Y
authors.initials: KY
authors.lastname: Chiu
authors.forename: C-K
authors.initials: CK
authors.lastname: Su
authors.affiliation: Wan-Yu Lin, MD, Department of Nuclear Medicine, Taichung Veterans General Hospital, 1650, Taiwan Boulevard, Sec. 4, Taichung 407, Taiwan, Tel. (886)4/23 74 13 49, Fax (886)4/23 74 13 48, E-mail: wylin@vghtc.gov.tw.
authors.forename: W-Y
authors.initials: WY
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D017060:Patient Satisfaction; D018802:Patient-Centered Care / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods; D001743:Urinary Bladder / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D014554:Urination
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Bladder cancer; FDG PET/CT; protocol; urinary FDG activity